Effectiveness and tissue compatibility of a 12-week treatment of chronic venous leg ulcers with an octenidine based antiseptic - a randomized, double-blind controlled study

被引:33
|
作者
Vanscheidt, Wolfgang
Harding, Keith [1 ]
Teot, Luc [2 ]
Siebert, Joerg [3 ]
机构
[1] Cardiff Univ, Wound Healing Res Unit, Cardiff CF14 4XN, S Glam, Wales
[2] Hop Lapeyronie, F-34295 Montpellier 5, France
[3] Schulke & Mayr GmbH, D-22851 Norderstedt, Germany
关键词
Antiseptic agent; Chronic venous leg ulcer; Octenidine dihydrochloride; Phenoxyethanol; Tissue tolerability; DIHYDROCHLORIDE; WOUNDS;
D O I
10.1111/j.1742-481X.2011.00886.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The aim of this study was to evaluate the cytotoxic effect of octenidine dihydrochloride/phenoxyethanol (OHP) found in vitro by conducting a randomized, double-blind controlled clinical study focusing on its safe and effective use in chronic venous leg ulcers. In total, 126 male and female patients were treated with either OHP (n = 60) or Ringer solution (n = 66). The treatment lasted over a period of maximum 12 weeks. For the assessment of the wound-healing process, clinical outcome parameters were employed, that is, time span until 100% epithelization, wound status and the wound surface area were analysed. Side effects were recorded during the study period. The median time to complete ulcer healing was comparable between the OHP and Ringer solution groups (92 versus 87 days; P = 0.952), without being influenced by wound size or duration of the target ulcer (P-values: 0.947/0.978). In patients treated with OHP, fewer adverse events (AEs) were observed compared with the Ringer group (17% versus 29% of patients reported 20 versus 38 AEs). OHP is well suitable for the treatment of chronic wounds without cytotoxic effects. Furthermore, OHP does not impair the wound healing in chronic venous ulcers.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 3 条
  • [1] The effectiveness of hyperbaric oxygen therapy for healing chronic venous leg ulcers: A randomized, double-blind, placebo-controlled trial
    Thistlethwaite, Kenneth R.
    Finlayson, Kathleen J.
    Cooper, P. David
    Brown, Bebe
    Bennett, Michael H.
    Kay, Graeme
    O'Reilly, Maria T.
    Edwards, Helen E.
    WOUND REPAIR AND REGENERATION, 2018, 26 (04) : 324 - 331
  • [2] Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: A phase II randomized, double-blind, placebo-controlled pilot trial
    Cox, C.
    Fry, K.
    Sivakumaran, Y.
    Spelman, L.
    Khosrotehrani, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (08) : E973 - E975
  • [3] EFFECT of daily antiseptic bathing with octenidine on ICU-acquired bacteremia and ICU-acquired multidrug-resistant organisms: a multicenter, cluster-randomized, double-blind, placebo-controlled, cross-over study
    Schaumburg, Tiffany
    Koehler, Norbert
    Breitenstein, Yasmine
    Kolbe-Busch, Susanne
    Hasenclever, Dirk
    Chaberny, Iris F.
    INTENSIVE CARE MEDICINE, 2024, 50 (12) : 2073 - 2082